United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 1

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 1 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderDexcom · 55

Strongest available pathStryker · +16.2%

Widest latest marginResMed · 27.2%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DXCM · Nasdaq

Dexcom

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1999WILMINGTON$34.27B market cap

View full Companies Radar profile

55Moderate

Snapshot price$90.82as of page date

Monthly-close return-32.5%five-year window

FY2025 revenue$4.66BDEXCOM INC

Net margin17.9%FY2025

P/E snapshot35.9xone ratio, not a verdict

Prism attention9.3%share across these five

Filing track recordRevenue, USD billions

+90.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.5%

52-week position95% through range

$54.11$92.59

News mentions8.5K

Community mentions83.7Kpartial coverage

U.S.-scope patents4656

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position7/100
Capital-event signal64/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 11 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2BDX · NYSE

Becton Dickinson

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1897Franklin Lakes$51.62B market cap

View full Companies Radar profile

50Moderate

Snapshot price$189.5as of page date

Monthly-close return-2.5%five-year window

FY2025 revenue$21.84BBECTON DICKINSON & CO

Net margin7.7%FY2025

P/E snapshot32.8xone ratio, not a verdict

Prism attention7.8%share across these five

Filing track recordRevenue, USD billions

+7.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%

52-week position95% through range

$127.6$193.1

News mentions7.2K

Community mentions225partial coverage

U.S.-scope patents25013

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position33/100
Capital-event signal24/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 26 M&A involvements, 11 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3SYK · NYSE

Stryker

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1941PLYMOUTH$126.84B market cap

View full Companies Radar profile

48Cautious

Snapshot price$330.7as of page date

Monthly-close return+16.2%five-year window

FY2025 revenue$25.12BSTRYKER CORP

Net margin12.9%FY2025

P/E snapshot34.2xone ratio, not a verdict

Prism attention29.2%share across these five

Filing track recordRevenue, USD billions

+46.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 10.1%

52-week position43% through range

$281.0$396.9

News mentions26.9K

Community mentions2.4Kpartial coverage

U.S.-scope patents10742

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position39/100
Capital-event signal28/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 7 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 135 M&A involvements, 18 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4RMD · NYSE

ResMed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2010San Diego, California$34.67B market cap

View full Companies Radar profile

44Cautious

Snapshot price$240.3as of page date

Monthly-close return-18.9%five-year window

FY2025 revenue$5.15BRESMED INC

Net margin27.2%FY2025

P/E snapshot23.0xone ratio, not a verdict

Prism attention4.7%share across these five

Filing track recordRevenue, USD billions

+61.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.6%

52-week position57% through range

$180.3$284.9

News mentions4.3K

Community mentions22.9Kpartial coverage

U.S.-scope patents702

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position16/100
Capital-event signal5/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 25 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5BAX · NYSE

Baxter

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1931Deerfield, Illinois$13.51B market cap

View full Companies Radar profile

38Cautious

Snapshot price$26.13as of page date

Monthly-close return-66.0%five-year window

FY2025 revenue$11.24BBAXTER INTERNATIONAL INC

Net margin-8.5%FY2025

P/E snapshot12.8xone ratio, not a verdict

Prism attention49.0%share across these five

Filing track recordRevenue, USD billions

-12.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -3.2%

52-week position73% through range

$15.73$30.00

News mentions45.0K

Community mentions1.7Kpartial coverage

U.S.-scope patents11259

Prism InsightsWhat sits behind the readiness signal
Observed risk 12/100higher means more observed risk

Earnings signal53/100
Management stability55/100
Market position35/100
Capital-event signal34/100
Innovation pulse22/100

Management signal

Leadership churn is flagged elevated; 4 key-person events were recorded in the latest 360-day window.

Market activity

Available history contains 55 M&A involvements, 41 asset-acquisition events and 14 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 6 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Stryker

+16.2%

Becton Dickinson

-2.5%

ResMed

-18.9%

Dexcom

-32.5%

Baxter

-66.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Stryker

$25.12B

Becton Dickinson

$21.84B

Baxter

$11.24B

ResMed

$5.15B

Dexcom

$4.66B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

ResMed

27.2%

Dexcom

17.9%

Stryker

12.9%

Becton Dickinson

7.7%

Baxter

-8.5%

Prism news attention

Normalized share across these five names; attention is not quality.

Baxter

49.0%

Stryker

29.2%

Dexcom

9.3%

Becton Dickinson

7.8%

ResMed

4.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Baxter leads the conversation

It holds 49.0% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $11.24B.

Price path

Stryker leads the available price paths

Its monthly-close return is +16.2% for the five-year window. At the other end, Baxter is -66.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

ResMed has the widest latest margin

Its FY2025 net margin is 27.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Baxter shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 12.8x while its five-year window price return is -66.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DXCM

Dexcom

8,512available Prism news records

Prism top themes

Price action & investor response

415

Macro demand & rates

256

Earnings & financial performance

206

Legal, arbitration & regulatory

148

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-18.8%1,611 latest 12m vs 1,983 prior 12m

Machine-classified coverage tone

80.6% positive+18.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

continuous glucose monitor 247remote glucose monitoring 232flash glucose monitoring 198smartwatch health monitor 188interstitial glucose monitoring 166advanced diabetes devices 145self-monitoring blood glucose 140glucose trends analysis 131

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-28 · trend and themes shown through 2026-06

Areas of research · BDX

Becton Dickinson

7,210available Prism news records

Prism top themes

Price action & investor response

174

Capital allocation & transactions

131

Leadership & governance

Earnings & financial performance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.4%937 latest 12m vs 950 prior 12m

Machine-classified coverage tone

92.5% positive+3.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 37stock price 32stem cell banking 23investment deal 23stock surge 21cell-based therapies 18device-biologic combination 17antimicrobial resistance surveillance 16

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · SYK

Stryker

26,860available Prism news records

Prism top themes

Price action & investor response

301

Capital allocation & transactions

255

Leadership & governance

195

Earnings & financial performance

170

Macro demand & rates

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+8.8%3,745 latest 12m vs 3,441 prior 12m

Machine-classified coverage tone

63.8% positive-13.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cyber espionage 233digital sabotage 182state-sponsored hacking 167electronic warfare 153critical infrastructure attacks 140military parades 135military funerals 105robotic surgery 105

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · RMD

ResMed

4,317available Prism news records

Prism top themes

Price action & investor response

240

Earnings & financial performance

155

Macro demand & rates

102

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+12.0%571 latest 12m vs 510 prior 12m

Machine-classified coverage tone

83.6% positive-1.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 59cpap machine 33stock price 30earnings report 27investment deal 23cpap mask 23quarterly results 22market rally 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-31–2026-06-19 · trend and themes shown through 2026-06

Areas of research · BAX

Baxter

44,971available Prism news records

Prism top themes

Leadership & governance

229

Earnings & financial performance

144

Capital allocation & transactions

104

Price action & investor response

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-35.1%3,169 latest 12m vs 4,881 prior 12m

Machine-classified coverage tone

70.8% positive+3.0 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

prosecutorial misconduct challenges 51prosecutorial misconduct 42stock performance 41earnings report 40ceo change 39lawyer series 37college playoffs 36election official misconduct 32

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-15 · trend and themes shown through 2026-07

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DXCM

Dexcom

83,701 mentions

Products, pricing and logistics

72,915

Stock and valuation

596

Workplace and hiring

139

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 83,701 records remained after filtering.

BDX

Becton Dickinson

225 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 225 records remained after filtering.

SYK

Stryker

2,363 mentions

Workplace and hiring

1,114

Products, pricing and logistics

489

Stock and valuation

223

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 2,363 records remained after filtering.

RMD

ResMed

22,949 mentions

Products, pricing and logistics

20,932

Stock and valuation

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 22,949 records remained after filtering.

BAX

Baxter

1,681 mentions

Products, pricing and logistics

546

Stock and valuation

Workplace and hiring

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,681 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DXCM

Dexcom

through 2026-04-30

Earnings releases 61Lawsuits 41Leadership changes 18Company announcements 9Listing / IPO 4

2026-04-30
Earnings releases
Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months ended March 31, 2026.
2026-03-02
Leadership changes
Upon his return, Sayer resumed his duties and responsibilities as executive chair.
2025-09-11
Lawsuits
A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BDX

Becton Dickinson

through 2026-03-20

Earnings releases 10M&A 10Asset acquisitions 4Company announcements 2Lawsuits 2

2026-03-20
Asset acquisitions
Waters completed its $18.8 billion buy of Becton Dickinson’s biosciences and diagnostics business last month.
2026-02-11
Earnings releases
Based on Becton Dickinson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.25 billion and a net profit of $382 million.
2026-02-09
Business contracts
Waters on Wednesday announced the completion of its $18.8 billion deal to combine with Becton Dickinson's Biosciences & Diagnostic Solutions business.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SYK

Stryker

through 2026-05-01

Earnings releases 64M&A 29Leadership changes 14Company announcements 10Business contracts 4

2026-05-01
Earnings releases
Stryker reported sales of $6 billion in the quarter, representing year-over-year growth of 2.6%.
2026-03-26
Company announcements
Medical device maker Stryker said on Thursday its operations were steadily improving towards full capacity, after a cyberattack caused widespread disruption to its business.
2026-01-06
Asset acquisitions
VB Spine completed the acquisition of Stryker’s spine implant manufacturing facility in Cestas, France.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RMD

ResMed

through 2026-02-03

Earnings releases 53Leadership changes 14Company announcements 7M&A 5Business contracts 1

2026-02-03
Earnings releases
Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$1.45 billion and a net profit of A$399.08 million.
2025-12-01
Leadership changes
Karen Drexler has served as a ResMed director since November 2017
2025-05-01
M&A
Resmed (NYSE: RMD) + announced today that it acquired VirtuOx, a leading independent diagnostic testing facility (IDTF).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BAX

Baxter

through 2026-05-01

Leadership changes 43Company announcements 34Earnings releases 33Lawsuits 31Asset acquisitions 14

2026-05-01
Earnings releases
First quarter 2026, global sales from continuing operations totaled $2.7 billion and increased 3% on a reported basis and declined 1% on an organic basis. Adjusted earnings from continuing operations were $0.36 per share, a decrease of 35%.
2026-04-27
Board updates
Shafer then became non-executive chair of the board as the board went forward with a previous plan to separate the roles of board chair and CEO.
2026-03-14
Lawsuits
According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the defendants violated Federal Securities Laws.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Dexcom leads the readiness ranking

Its Prism readiness score is 55/100, the highest in this five-company comparison.

Open Dexcom in Companies Radar

Scale and margin leadership sit with Stryker and ResMed

Stryker has the largest displayed latest revenue at $25.12B; ResMed has the widest displayed latest margin at 27.2%.

Open Stryker in Companies Radar Open ResMed in Companies Radar

Comparisons

Strongest versus weakest available price path

Stryker is +16.2% for its five-year window; Baxter is -66.0% for its five-year window.

Open Stryker in Companies Radar Open Baxter in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $25.12B for Stryker to $4.66B for Dexcom. Entity and filing-period labels remain visible on the company cards.

Open Stryker in Companies Radar Open Dexcom in Companies Radar

Anomalies

Baxter has the widest attention-readiness rank gap

It ranks #1 by measured news attention (49.0%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Baxter in Companies Radar

Dexcom shows a price-operating divergence to inspect

Its displayed filing-revenue change is +90.4% while its available monthly-close return is -32.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Dexcom in Companies Radar

Explanations

Attention measures coverage volume, not quality

Baxter's 49.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Baxter in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Dexcom's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 55/100 score.

Open Dexcom in Companies Radar

Stress-test the largest divergence before forming a view

Compare Dexcom's profile with Stryker's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Dexcom in Companies Radar Open Stryker in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.